Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 8.3% in September

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 505,200 shares, a growth of 8.3% from the August 31st total of 466,600 shares. Based on an average daily trading volume, of 46,500 shares, the days-to-cover ratio is presently 10.9 days. Currently, 8.5% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price target on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd.

Greenwich LifeSciences Stock Down 3.5 %

GLSI traded down $0.51 during trading on Tuesday, hitting $13.86. 31,336 shares of the stock were exchanged, compared to its average volume of 42,669. Greenwich LifeSciences has a 1-year low of $7.58 and a 1-year high of $21.44. The stock has a fifty day moving average price of $14.44 and a two-hundred day moving average price of $15.05. The firm has a market capitalization of $178.52 million, a P/E ratio of -19.69 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). Analysts predict that Greenwich LifeSciences will post -0.81 EPS for the current year.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel bought 5,500 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were acquired at an average price of $13.18 per share, with a total value of $72,490.00. Following the transaction, the chief executive officer now owns 5,532,602 shares of the company’s stock, valued at $72,919,694.36. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders have acquired 11,300 shares of company stock valued at $160,500 over the last quarter. 52.86% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GLSI. Rhumbline Advisers purchased a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $117,000. Bank of New York Mellon Corp purchased a new stake in shares of Greenwich LifeSciences during the second quarter worth approximately $264,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after purchasing an additional 1,420 shares during the period. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.